pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 47 | Non-oncology: 31 Oncology: 16 |
| Under Consideration for Negotiation | 18 | Non-oncology: 11 Oncology: 7 |
| Completed Negotiations | 918 | With Letter of Intent: 792 Without agreement: 126 |
| Negotiations That Were Not Pursued | 113 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Conexxence | Fresenius Kabi Canada Ltd. | • treatment of postmenopausal women with osteoporosis at high risk for fracture; • treatment to increase bone mass in men with osteoporosis at high risk for fracture; • treatment to increase bone mass in men with nonmetastatic prostate cancer receiving an | |
| Bomyntra | Fresenius Kabi Canada Ltd. | • reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors; • treatment of adults and skeletally | |
| Blenrep (belantamab mafodotin) | GlaxoSmithKline Inc. | For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide. | |
| Dupixent | Sanofi Genzyme Canada | Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-a | |
| Blenrep (belantamab mafodotin) | GlaxoSmithKline Inc. | For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy. | |
| Yondelis | Xediton Pharmaceuticals Inc | in combination with doxorubicin as first-line treatment for advanced unresectable or metastatic uterine or soft tissue leiomyosarcoma | |
| Enhertu | AstraZeneca Canada Inc. | Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma |